Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2554-2559

  Boisen, M K ^a   Johansen, J S ^a   Dehlendorff, C ^b   Larsen, J S ^c   osterlind K ^d   Hansen, J ^e,f   Nielsen, S E ^g   Pfeiffer, P ^h   Tarpgaard, L S ^h   Hollander N H ⁱ   Keldsen, N ^j   Hansen, T F ^k   Jensen, B B ^l   Jensen, B V ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e Department of Oncology Aalborg Sygehus ^*  (Sweden)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g HILLERØD HOSPITAL   (Denmark)

^h ODENSE UNIVERSITY HOSPITAL   (Denmark)

ⁱ NAESTVED HOSPITAL   (Denmark)

^j HERNING HOSPITAL   (Denmark)

^k LILLEBAELT HOSPITAL   (Denmark)

^l ESBJERG HOSPITAL   (Denmark)

more..

Author keywords

Bevacizumab; Biomarker; Chemotherapy; Metastatic colorectal cancer; Primary tumor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CECUM CANCER; CLINICAL EFFECTIVENESS; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DESCENDING COLON; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REPEATED DRUG DOSE; SURVIVAL RATE;

BEVACIZUMAB; BIOMARKER; CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; PRIMARY TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CECUM; COLON, DESCENDING; COLON, SIGMOID; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS; RECTUM; SIGMOID NEOPLASMS; SURVIVAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84884722908     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt253     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
4. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
5. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
6. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
7. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
8. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
9. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
10. Popovici V, Budinska E, Tejpar S et al. Identification of a poor-prognosis BRAFmutant- like population of patients with colon cancer. J Clin Oncol 2012; 30: 1288-1295.
11. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337.
12. Bendardaf R, Buhmeida A, Hilska M et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 2008; 28: 3865-3870.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Qvortrup C, Jensen BV, Fokstuen T et al. A randomized study comparing shorttime infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. Ann Oncol 2010; 21: 87-91.
15. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing 2011.
16. Tie J, Gibbs P, Lipton L et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011; 128: 2075-2084.
17. Oxnard GR, Morris MJ, Hodi FS et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012; 104: 1534-1541.
18. Fyfe GA, Hurwitz H, Fehrenbacher L et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. ASCO Meeting Abstracts 2004; 22: 3617.
19. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334.
20. Cunningham D, Lang I, Lorusso V et al. Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX). ASCO Meeting Abstracts 2013; 31: 337.
21. Chibaudel B, Bonnetain F, Tournigand C et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist 2011; 16: 1228-1238.
22. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12: 642-653.
23. Giacchetti S, Bjarnason G, GarufiC et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24: 3562-3569.
24. Giacchetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.